Skip to content
WebMD: Better Information. Better Health.
Other search tools:Symptoms|Doctors|Videos

Multiple Sclerosis Health Center

This article is from the WebMD News Archive

Font Size
A
A
A

Cancer Drug Rituxan Cuts MS Flare-ups

Studies Show Multiple Sclerosis Patients Taking Rituxan Have Fewer Brain Lesions
By Charlene Laino
WebMD Health News
Reviewed by Louise Chang, MD

May 1, 2007 (Boston) -- A drug that is already used to treat cancer and rheumatoid arthritis cut by more than half the chance that people with multiple sclerosis would have their symptoms flare up over a six-month period, researchers report.

In two early studies, people taking the drug, Rituxan, also had fewer areas of damage, or lesions, in their brain than those on placebo.

"We believe that if we can prevent these lesions, we can modify the course of this disease," says researcher Stephen Hauser, MD, chairman of neurology at the University of California, San Francisco, and president of the American Neurological Association.

If the research pans out, "this would be a very attractive and probably blockbuster therapy," he tells WebMD.

The research was presented at the American Academy of Neurology's 59th Annual Meeting.

How Rituxan Works

The exact cause of multiple sclerosis (MS) is unknown. But the disease is thought to be triggered by a malfunction in the immune system that prompts immune cells to attack the brain and/or spinal cord. The most common form of multiple sclerosis is a relapsing-remitting form in which relapses or "attacks" of worsening neurologic function appear, and then disappear, for months or years at a time.

Like many other drugs for MS, Rituxan targets the immune system to help calm the inflammation that scars nerves, leading to disease progression. But Rituxan homes in on the immune system in a brand new way, Hauser says.

The drug works by targeting cells in the immune system called B cells, which make antibodies that contribute to the disease process. B cells also secrete chemicals that can encourage inflammation, he says.

Though never compared head-to-head, the early research hints that the drug is twice as effective as drugs such as interferon that are now used to treat multiple sclerosis, he says.

Also, it's more convenient, requiring only two infusions every six months or so instead of the daily to weekly injections associated with current therapies, Hauser says.

multiple sclerosis newsletter

While 2.5 million people worldwide are affected by MS, we're concerned about your specific case. Get the information you need from the health information provider you can trust.

webMD Video

Show or hide information about video: Yoga for MS   Yoga for MS

Yoga’s healing powers are now helping MS patients lead happier, healthier lives.

Watch Video: Yoga for MS (opens in a new window)

Show or hide information about video: Future of MS Treatment   Future of MS Treatment

Show or hide information about video: MS Profile: Smooth Sailing   MS Profile: Smooth Sailing

Show or hide information about video: Multiple Sclerosis and Exercise   Multiple Sclerosis and Exercise

Show or hide information about video: Reducing Urinary Incontinence   Reducing Urinary Incontinence